Reviva Pharmaceuticals Receives FDA Orphan Designation for Hypertension Therapy

Reviva Pharmaceuticals has been granted an orphan drug designation from the FDA for its pulmonary arterial hypertension candidate.

The candidate, RP5063, blocks serotonin receptors during cell signaling. In a clinical study, the therapy has been shown to reduce pulmonary arterial vessel wall thickness and muscular tissue by raising the blood oxygen to normal levels and significantly reducing cell mass levels.

There is currently no cure for pulmonary arterial hypertension.